Core Viewpoint - The agreement between Baiaosaitu-B and Yushibo aims to accelerate the development of bispecific antibody-drug conjugates (BsAD2C) through a structured evaluation mechanism [1] Group 1: Agreement Details - Baiaosaitu has entered into an option and licensing agreement with Yushibo, granting Yushibo the option for global exclusive licensing of two BsADC projects [1] - The agreement includes an upfront payment for the option, and upon exercise, Baiaosaitu will receive additional payments including option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and future product sales royalties [1] Group 2: Collaboration Background - This agreement deepens the collaboration initiated at the beginning of the year, which focused on evaluating and screening bispecific antibodies and dual-load antibody-drug conjugate (ADC) candidates with therapeutic potential [1] - The combination of Baiaosaitu's RenLite® fully human light chain antibody development platform and Yushibo's antibody-drug conjugate (AD2C) technology is seen as a promising technical pathway for the development of a new generation of BsAD2C [1] Group 3: Project Advancement - The collaboration aims to leverage the complementary strengths of both platforms to advance the design of next-generation ADC molecules, addressing limitations observed in traditional ADC projects [2] - The project team is steadily progressing through key evaluation milestones, with decisions based on ongoing research data and Yushibo's internal processes and option exercise criteria [2]
百奥赛图-B(02315.HK)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗体双药物偶联物项目